Trial NCT00751296

View at ClinicalTrials.gov 
Org. Study IDs: Rev-06-0099
Secondary IDs: RV-CLL-PI-0099

Last trial update was posted on 2016-06-16

MeSH Interventions

Lenalidomide

MeSH Conditions

Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid

Other Conditions

Chronic Lymphocytic Leukaemia

Stopping Reasons

Seven years of follow-up & final analysis done in Dec 2012.

Limitations And Caveats

Original study protocol used a starting lenalidomide dose of 10mg OD for 21days of a 28-day cycle, escalating weekly by 5mg to a target of 25mg daily. Toxicities reported with the first two enrolled patients lead to the current protocol amendment.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID